Lamellar Biomedical, a UK-based healthcare company treating dry eyes and mouths, has raised £3.3m ($5.3m) from a consortium including peer Barwell. Other investors included government-backed Scottish Enterprise, mutual fund manager Invesco Perpetual and angel network TRI Cap. Tri-Cap (£260,000), Barwell (£150,000) and others had provided £935,000 to Lamellar in September 2007. After the funding, Duncan…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
